



Malmö 16 August 2024

PRESS RELEASE

Aptahem receives patent protection in Israel for patent family 2

Aptahem AB (publ) announces today that the company has received patent protection in Israel for patent family 2 from the Israeli Patent Office.

With the approval in Israel of patent application 273759, the protection of the company's drug candidate Aptahem within patent family 2 in Israel, Israeli Patent No. 273759, is valid until the end of 2038.

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Aptahem, is currently in early clinical phase. Aptahem has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.